摘要
近年来,免疫检查点抑制剂的出现改变了多种恶性肿瘤的治疗方式,但其常造成包括心血管系统在内的免疫相关不良事件。诸多对免疫检查点抑制剂治疗相关心血管不良事件的研究主要局限在心肌炎,而最近一些临床研究表明,免疫检查点抑制剂与动脉粥样硬化的发展和恶化可能相关。现就免疫检查点抑制剂相关动脉粥样硬化性心血管疾病可能的病理机制及临床意义进行综述,以期提高临床医生对动脉粥样硬化性心血管疾病的意识并警惕其发生。
While immune checkpoint inhibitors have transformed how some malignant tumors are treated in recent years,it has also resulted in the occurrence of unique immune-related adverse events,including the cardiovascular system.Some recent clinical research suggests that immune checkpoint inhibitors may be connected to the onset and progression of atherosclerosis,however many investigations on cardiovascular adverse events due to treatment with immune checkpoint inhibitors are primarily limited to myocarditis.This article reviews the possible pathological mechanism and clinical significance of immune checkpoint inhibitors related atherosclerotic cardiovascular disease,in order to improve clinicians’awareness of atherosclerosis cardiovascular disease and guard against its occurrence.
作者
陆睿
廖祎
王敏
林心情
鲁明军
LU Rui;LIAO Yi;WANG Min;LIN Xinqing;LU Mingjun(Department of Cardiology,The First Affiliate Hospital of Guangzhou Medical University,Guangzhou 510120,Guangdong,China;Department of Respiratory,The First Affiliate Hospital of Guangzhou Medical University,Guangzhou 510120,Guangdong,China)
出处
《心血管病学进展》
CAS
2024年第2期141-144,150,共5页
Advances in Cardiovascular Diseases
基金
广州市科技计划项目(202102010180)
广东省援疆科技项目(2017B0202470)。
